3560 studies found for:    Open Studies | "Carcinoma"
Show Display Options
Rank Status Study
21 Unknown  Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Gemcitabine, UFT
22 Recruiting AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
Conditions: Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Therapeutic Conventional Surgery;   Drug: WEE1 Inhibitor MK-1775
23 Recruiting Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
24 Recruiting F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Interventions: Drug: Arm A: F16IL2 in combination with paclitaxel;   Drug: Arm B: Paclitaxel
25 Not yet recruiting A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Conditions: Advanced Adult Hepatocellular Carcinoma;   Advanced Fibrolamellar Carcinoma
Intervention: Drug: ENMD-2076
26 Unknown  the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
Conditions: Stage I Hepatocellular Carcinoma;   Stage II Hepatocellular Carcinoma
Interventions: Drug: the ginsenoside Rg3;   Drug: Placebo
27 Unknown  Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients
Conditions: Cirrhosis With Hepatocellular Carcinoma;   Cirrhosis Without Hepatocellular Carcinoma
Interventions: Biological: Serum, plasma and DNA samples;   Procedure: Radiological exploration by CT scan or MRI
28 Unknown  Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Conditions: Clear-cell Renal Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
29 Recruiting Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Conditions: Poorly Differentiated Neuroendocrine Carcinoma,;   Neuroendocrine Carcinoma, Grade 3;   Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
Intervention: Drug: Everolimus (Afinitor®)
30 Recruiting Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy
Conditions: Bladder Cancer;   Bladder Carcinoma;   Transition Cell Cancer;   Muscle Invasive Bladder Carcinoma
Interventions: Procedure: Transurethral Resection of the Bladder Tumor & Cystoscopy;   Drug: Cisplatin;   Drug: Gemcitabine;   Radiation: Intensity Modulated Radiation Therapy;   Behavioral: Quality of Life Questionnaires;   Genetic: Urine Collection for Molecular Analysis;   Genetic: Blood Collection for Molecular Analysis
31 Recruiting First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Conditions: Transitional Cell Carcinoma;   Bladder Carcinoma;   Urothelial Carcinoma
Interventions: Drug: Everolimus;   Drug: Paclitaxel
32 Recruiting Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Condition: Non Small Cell Lung Carcinoma
Intervention:
33 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
34 Recruiting Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Conditions: Cancer of Head and Neck;   Head and Neck Cancer;   Neoplasms, Head and Neck;   Carcinoma, Squamous Cell of Head and Neck;   Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma, Head and Neck
Interventions: Biological: MK-3475;   Procedure: Surgery;   Radiation: Intensity modulated radiation therapy;   Radiation: Image-guided radiation therapy;   Drug: Cisplatin
35 Recruiting Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Conditions: Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: Drug: vorinostat;   Drug: cisplatin;   Radiation: radiation therapy;   Procedure: Correlative Studies
36 Recruiting TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Conditions: Stage III Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma
Intervention: Drug: TPF induction chemotherapy
37 Recruiting Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Conditions: Anal Canal Squamous Cell Carcinoma;   Metastatic Anal Canal Carcinoma;   Recurrent Anal Canal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
38 Recruiting A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
Conditions: Carcinoma Neuroendocrine;   Small Cell Lung Carcinoma;   Malignant Epithelial Neoplasms
Interventions: Drug: Belinostat;   Drug: Cisplatin;   Drug: Etoposide
39 Recruiting A Study of rSIFN-co in Subjects With Advanced Solid Tumors
Conditions: Solid Tumors;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Renal Cell;   Melanoma;   Carcinoma, Hepatocellular;   Cancer of Colon
Interventions: Drug: rSIFN-co;   Drug: rSIFN-co (Recommended Dose)
40 Recruiting Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
Conditions: Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years